Page 353 - Glucose Monitoring Devices

360 Index

Error grid analysis (EGA) H
clinical implications, 43 Hollow-needle microsensor array, 116e117
consensus error grid, 45e47, 46f Human regular insulin, 260
design, 43 Hybrid closed-loop systems, 151e152
“failure to detect and treat” ranges, 45 Hybrid infinite impulse response filter, 278
inaccurate estimations, 57e58 Hypoglycemia, 45e46, 136e137, 275
patient scenarios, 46e47 complications, 257
risk categories, 45e46 fear of hypoglycemia (FOH), 276
SMBG values vs. reference values, 44e45 incidence rates, 257
specific treatment range, 45 predictive low glucose suspend (PLGS)
surveillance error grid (SEG), 46e47, 48f technology. See Predictive low glucose
target range, 45, 45f suspend (PLGS) technology
zones, 43e44, 44f severe, 275e276
Eversense CGM System, 128e129
Exponentially weighted moving average (EWMA) I
filter, 308e309 Inaccurate blood glucose monitoring (BGM)
systems
F behavioral variability, 56
Fear of hypoglycemia (FOH), 276 clinical outcomes, 55
First-order diffusion model, 244 complex system, 53e54
Flash glucose monitoring system computer simulations, 58
flash glucose monitor (FGM) device, 53 consequences, 57e62
Freestyle Librelink App, 150e151 device and lot variability, 56
HART CGM study, 151 diabetes management system, 53f
IMPACT trial, 150e151 diabetes-related complications, 55
Fluorescent glucose sensors, 117 error and bias, 65e66, 69
Fully closed-loop (FCL) system, 334 financial impact, 67e68, 68f
Fuzzy logic (FL) financial outcomes, 56
algorithm, 333 hypoglycemia, 53e54
control, 294, 297 long-term health complications, 62
HbA1c effect, 61, 62f
G linear regression model, 61
Gaussian model, 82e83 Markov cohort modeling approach, 61, 62f
Generalized predictive control (GPC), 307 population-level published literature, 61
Glucagon, 296 low blood glucose index (LBGI), 60
Glucometers, 3e4 measurement errors, 57e58
Glucose and glucose/galactose-binding protein metabolic variability, 57
(GGBP), 117 modeling and simulation, 70
Glucose control parameters behavioral modeling, 58e59
glucose variability, 137 glucose monitoring devices, 59
glycated hemoglobin (HbA1c), 136 integrated metabolic/behavioral simulation, 59
hypoglycemia, 136e137 mean absolute relative difference (MARD),
Glucose dehydrogenase-based test strips, 4e5 60e61
Glucose oxidase, 4e5 metabolic models, 58
Glucose oxidase (GOx)-based continuous glucose in silico accuracy study, 59e61, 60f
monitoring (CGM) systems, 113e115 patient behavior, 54e55, 54f, 70
Glucose oxidase-based sensing, 113 physiological variability, 56
Glucose sensor hydrogel technology, 117 quality of life, 55
Glycated hemoglobin (HbA1c), 135e136 severe hypoglycemia events (SHE), 55
Glycemic load, 138 short-term and long-term consequences, 52f
Glycemic risk index (GRI), 311e312, 312f therapy modes, 56e57
Guardian sensor 3, 336e337 time span, 57